Abstract: A controlled release composition comprising nimesulide as an active agent formulated as a gastroretentive system, preferably as a solid oral dosage form is provided, wherein the residence time of the active agent is increased in the stomach, duodenum, jejunum or ileum. The present invention also provides process of preparing such dosage form and methods of using such dosage form compositions. The dosage form compositions are preferably administered once-a-day or twice-a-day and are particularly very useful in the prophylaxis or treatment of NSAID indicated disorder(s) such as acute painful conditions like post-operative trauma, pain associated with cancer, sports injuries, migraine headache and the like, or chronic diseases such as arthritis and the like.

Abstract: A pharmaceutical composition of anti-tubercular drugs for oral use comprising Rifampicin and/or Isoniazid wherein the bioavailability of Rifampicin and/or other drugs is enhanced. Preferably the bioavailability of Rifampicin is enhanced by preventing its degradation caused by presence of Isoniazid. Rifampicin and/or Isoniazid may be present in delayed release and/or extended release form such that minimal amount of the drug is dissolved between pH 1 and 4. preferably delayed release of Rifampicin and/or Isoniazid is achieved by treating the drugs with pH sensitive polymers.

Abstract: A novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds, and ezetimibe, its salts, analogs or derivatives thereof optionally with pharmaceutically acceptable excipients, and process of preparation of such composition is provided. Also provided are method of treatment and use of such composition for reducing abnormal lipid parameters associated with hyperlipidemia.

Abstract: A composition comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds, and nicotinic acid, its salts or derivatives thereof optionally with excipients, and process of preparation of such composition is provided. Also provided are method of treatment and use of such composition for reducing abnormal lipid parameters associated with hyperlipidemia. The compositions of the present invention are useful pharmaceutically or as a dietary supplement.

Abstract: A method and apparatus for defining a circuit operation, such as a charged particle beam operation to perform a circuit edit and define a probe point. Circuit operation definition is performed in a front-end environment with access to integrated circuit computer aided design tools providing logic level and layout level information concerning the integrated circuit. The front-end environment incorporates circuit operation optimization methods to identify optimal locations for a circuit operation. A back-end environment, such as a charged particle tool computing platform, is adapted to receive one or more files, which may include a truncated layout file with circuit operation location information, for use in further defining a circuit operation and/or performing the circuit operation.

Abstract: A novel fast dissolving pharmaceutical composition in solid dosage form with prolonged sweet taste which comprises (a) At least one pharmaceutically active agent, (b) At least one water soluble sugar, (c) At least one non-sugar sweetner in normal fast release form and (d) At least one non-sugar sweetner in a mucoadhesive slow release form.

Abstract: The invention relates to novel compositions comprising of an extract of the plant Euphorbia prostrata, particularly with pharmaceutically acceptable carrier(s)/base(s), optionally with additional therapeutic agent(s) useful for the treatment of anorectal disease and colonic diseases such as hemorrhoids, fissures, cracks, fistulas, abscesses, inflammatory bowel disease, and the like. The nove( compositions possess properties to contro( inflammation, prevent capillary bleeding and fragility in mammalians, particularly human beings. Process for the preparation of such novel compositions comprising an extract of the plant Euphorbia prostrata and pharmaceutically acceptable carrier(s)/base(s) useful for the treatment of anorectal disease including hemorrhoids, and colonic diseases are also provided. The composition comprise of flavonoidal and phenolic constituents extracted from the plant Euphorbia prostrata that possess anti-inflammatory, analgesic, haemostatic and wound-healing properties.

Abstract: The invention is related to an oral immediate release formulation of Benzazepin-1-acetic acid derivatives comprising a) said active substance in an amount of up to 65% of the total weight of the formulation; b) at least 10% w/w an alkaline compound or a mixture of alkaline compounds; c) between 0.1 and 10% of one or more surfactants, and d) optionally comprises auxiliary materials an amount of between 1% and 45% of the total weight of the formulation.

Abstract: A composition for targeted vesicular for treatment of H-Pylori infections and for protection of the cell. The composition contains lectins, phospholipids, sterols, and one or more drugs. The composition is useful for treating H-Pylori infections and other diseases associated therewith and also helps in protecting cell walls.

Abstract: A pharmaceutical composition of anti-tubercular drugs for oral use comprising Rifampicin and/or Isoniazid wherein the bioavailability of Rifampicin and/or other drugs is enhanced. Preferably the bioavailability of Rifampicin is enhanced by preventing its degradation caused by presence of Isoniazid. Rifampicin and/or Isoniazid may be present in delayed release and/or extended release form such that minimal amount of the drug is dissolved between pH 1 and 4. preferably delayed release of Rifampicin and/or Isoniazid is achieved by treating the drugs with pH sensitive polymers.

Abstract: A real-time water quality monitoring and action trigger system driven by an expert system for managing distributed and redundant water sources. The monitoring systems are installed at the water sources and real-time analysis is conducted at regular intervals and/or by triggering. The results are forwarded to a centralized quality control center via advanced data communications networks. The management center is equipped with a highly reliable computer system running water quality control expert system. Based on the field data, appropriate actions can be derived via applying the rules and/or models built in the expert system and proper triggers are sent to the treatment facilities at the water sources through data networks. The expert system is an open system that not only can learn and refine the rules and/or models but also incorporate new inputs from qualified personnel.

Abstract: A composition for targeted vesicular for treatment of H-Pylori infections and for protection of the cell. The composition contains lectins, phospholipids, sterols, and one or more drugs. The composition is useful for treating H-Pylori infections and other diseases associated therewith and also helps in protecting cell walls.

Abstract: A Parenteral Water-miscible non-intensely coloured injectable composition of Non-steroidal anti-inflammatory drugs is disclosed. The invention utilizes solubilization techniques to achieve sufficiently high concentrations of Nimesulide suitable to deliver therapeutic doses in conveniently small volumes using water and without any salt form or complexing agent of Nimesulide. In the composition of the invention all the ingredients of the base are hydrophillic. The hydrophillic base serves the advantage of better miscibility with body fluids, faster drug disposition and better compatibility with the tissue environment.

Abstract: A homogenous substantially alcohol free composition of Cyclosporin which comprises a cyclosporin in a hydrophilic carrier medium comprising propylene glycol, esters of propylene glycol with C4 to C12 fatty acids and polyoxyethylene hydrogenated castor oils wherein the ingredients are present in the following range, Cyclosporin 1-25% w/w, Propylene Glycol 2.5-70% w/w, Esters of propylene glycol with C4 to C12 fatty acids 2.5-70% w/w and Polyoxyethylene hydrogenated Castor oils 2.5-70% w/w.

Abstract: A Novel Composition for targeted vesicular for treatment of H-Pylori infections and for protection of the cell is disclosed. The Composition Comprises Lectins, Phospholipids sterols an one or more drugs. The Composition is useful since not only it treats H-Pylori infections and other diseases associated therewith but also helps in protection of the cell walls.

Abstract: A novel composition of Nimesulide and salts thereof and Cetrizine possessing antileukotriene, antihistaminic, antiallergic and antiinflammatory action is disclosed. The composition is useful in the cure of allergic disorders such as rhinitis, bronchitis, asthama, urticaria and the like.

Abstract: The invention disclosed a homogenous substantially alcohol free composition of Cyclosporin which comprises a Cyclosporin in a hydrophilic carrier medium comprising propylene glycol, esters of propylene glycol with C4 to C12 fatty acids and polyoxyethylene hydrogenated castor oils wherein the ingredients are present in the following ranges, Cyclosporin 1-25% w/w, Propylene Glycol 5-50% w/w, Esters of Propylene Glycol with C4 to C12 fatty acids 10-40% w/w and Polyoxyethylene hydrogenated Castor oils 25-60% w/w.

Abstract: A Parenteral Water-miscible non-intensely colored injectable composition of Non-steroidal anti-inflammatory drugs is disclosed. The invention utilizes solubilization techniques to achieve sufficiently high concentrations of Nimesulide suitable to deliver therapeutic doses in conveniently small volumes using water and without any salt form or complexing agent of Nimesulide. In the composition of the invention all the ingredients of the base are hydrophillic. The hydrophillic base serves the advantage of better miscibility with body fluids, faster drug disposition and better compatibility with the tissue environment.

Abstract: A novel composition for increasing the bioavailability of Non-steroidal Anti-inflammatory Drugs (NSAIDs), particularly those belonging to the category which exhibits its activity by selectively inhibiting cyclooxygenases-II (COX-II) and/or lipooxygenases, is disclosed. The composition is characterized in having clinically significant increased bioavailability when compared to the known compositions of the drugs. The pharmaceutical compositions comprise NSAIDs and Piperine, as herein disclosed. Enhanced bioavailability of NSAIDs results in the reduction of both dosages and dose-related side effects.

Abstract: A novel homogenous alcohol free, free flowing, clear and transparent pharmaceutical composition containing Cyclosporin is disclosed. The amount of Cyclosporin is easily measurable at a wide range of temperature of 15.degree. to 45.degree. C. The composition comprises a Cyclosporin in a hydrophillic carrier medium comprising propylene glycol, a transesterification product of a natural vegetable oil triglyceride and a polyalkylene polyol--such as Apricot Kernel Oil Polyethylene glycol 6 esters--such as Labrafil M1944 and polyethylene hydrogenated castor oils--such as Cremophor RH 40 and Glycerol Triacetate or Triacetin.